Optionicity: ImmunityBio (IBRX) Analysis

Note: Click on the chart and scroll for continuous zoom

Not included: trials with a status of withdrawn, terminated, unknown, or started prior to 2020.
Trial date range starts with the primary study completion date ends with the study completion published on clinicaltrials.gov.
For the timeline's readability and usability reasons, the smallest increment between the primary and study completion date is 10 days. There are a few cases where those dates are identical on clinicaltrials.gov.
IBRX completes and withdraws studies without announcement, so there's no way to know if/when results are forthcoming. They also occasionally release preliminary data prior to study completion.
Reporting requirement for National Cancer Institute-sponsored studies: Within 12 months of the earlier of estimated/actual primary completion date.
Drugs may have multiple names. For example: Anktiva = N-803 = Alt-803 = Inbakicept

Trial Timeline